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Abstract: Helicobacter pylori (Hp) management has undoubtedly resulted in a notable economic burden
on healthcare systems globally, including Greece. Its cost has never been estimated so far, especially
during the recent 10-year unprecedented financial crisis. Direct medical and procedural costs for one
attempt “outpatient” Hp eradication treatment were estimated as the following: (I) first-line regimens:
10 and 14 days standard triple, 10 and 14 days sequential, 10 and 14 days concomitant non-bismuth
quadruple, 14 days hybrid, (II) second-line salvage regimens: 10 and 14 days levofloxacin-containing
triple regimens. Treatment costs using prototypes and/or generic drugs were calculated. Drug prices
were collected and confirmed from two official online medical databases including all medicines
approved by the Greek National Organization for Medicines. Regimens based on generics were
more affordable than prototypes and those including pantoprazole yielded the lowest prices (mean:
27.84 €). Paradoxically, 10-day concomitant and 14-day hybrid regimens (currently providing good
(90–94%) first-line eradication rates in Greece) cost the same (mean: 34.76 €). The expenditures for Hp
eradication treatment regimens were estimated thoroughly for the first time in Greece. These data
should be taken into account by Public Health policymakers both in Greece and the European Union,
aiming for a better and less expensive therapeutic approach.
Keywords: Helicobacter pylori; Hp infection; treatment cost; eradication regimens
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1. Introduction
Greece has been experiencing a financial decline during the last decade, which is a recognizable
representative of the global crisis, and the resultant austerity policies have affected national healthcare
expenditures [1,2]. A 35% reduction in the National Health System resources was noted between the
onset of the crisis and 2016; concurrently, spending for health was among the lowest in Europe [3].
This reduction, at least at the beginning, did not affect medication costs, a fact that is quite obvious
considering that in 2013, proton pump inhibitors (PPIs) in Greece were among the most expensive
drugs compared to other European countries (similar to Switzerland) [4]. Additionally, the prescription
of generics was sluggish in Greece until it became compulsory for both doctors and pharmacists to
provide patients with the most affordable choices [4,5].
Helicobacter pylori infection (Hp-I) affects 40.2–64.0% of the Greek population, following the
global prevalence and an increasing tendency of infectious diseases in our country attributed to
economic hardships and migratory flows [6–9]. According to current guidelines [10], peptic ulcer
disease, gastritis, gastric atrophy, gastric cancer, gastric mucosa-associated lymphoid tissue lymphoma,
idiopathic thrombocytopenic purpura or iron-deficiency anemia necessitate a Hp test and treat strategy,
whereas a plethora of further disorders have been connected with Hp-I, such as colorectal cancer and
esophageal adenocarcinoma. In certain subpopulations, insulin resistance, non-alcoholic liver disease,
and neurodegenerative conditions have also been associated with Hp-I [10–16].
To date, Hp eradication treatment strategies have been revised in 2017 considering the increasing Hp
antibiotic resistance. Quadruple regimens in high clarithromycin resistant regions in the absence of bismuth
containing drugs were suggested [10]. Although clarithromycin resistance in Greece overwhelms the
minimum acceptable value of 15% [10,17,18], many practitioners (especially non-gastroenterologists)
prescribe outdated regimens such as a 10- or 14-day triple regimen. Hp eradication rates have been the
most acceptable and reasonable way to compare regimens, although current financial circumstances
require an additional economic approach to assist clinicians in the decision-making process. In this
study, we aimed to estimate the direct costs of one attempt “outpatient” eradication treatment for all
non-bismuth prescribed regimens in our country, considering the prices of both prototypes and generics.
2. Materials and Methods
In order to calculate the direct aggregated pharmaceutical costs for one attempt “out-patient”
non-bismuth eradication therapies for Hp we worked in four steps, as presented in Figure 1. A wide
spectrum of potential Hp eradication treatment regimens were included in our survey (Figure 2):
• First-line regimens:
i. 10-day standard triple
ii. 14-day standard triple,
iii. 10-day sequential,
iv. 14-day sequential,
v. 10-day concomitant non-bismuth quadruple
vi. 14-day concomitant non-bismuth quadruple,
vii. 14-day hybrid,
• Second-line salvage regimens:
i. 10-day levofloxacin-containing triple regimen,
ii. 14-day levofloxacin-containing triple regimen.
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Figure 1. The four step working pathway to calculate the direct aggregated pharmaceutical costs for
one attempt “outpatient” non-bismuth eradication therapies of Helicobacter pylori (Hp). All prototypes
and generics drugs included in both first- and second-line treatment regimens were collected to
calculate the overall cost per therapeutic choice. * Data regarding drug prices were collected and
double-checked using two databases; a governmental website of the Greek National Organization for
Medicines (https://www.eof.gr/web/guest/home) and a commercial, routinely used medical platform
(https://www.galinos.gr/). PPI: proton pump inhibitor.
Figure 2. Detailed outline of first- and second-line Hp-I eradication regimens. Ten- and 14-day standard
triple treatment includes PPI twice a day (b.i.d.), amoxicillin 1 g b.i.d., and clarithromycin 500 mg b.i.d.
for ten and fourteen days, respectively. The concomitant regimen includes a continuous intake of PPI
b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and metronidazole 500 mg b.i.d. for either ten
or fourteen days. Patients treated with the 10-day sequential regimen received amoxicillin 1 g b.i.d. and
PPI b.i.d. for five days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and PPI
b.i.d. for an additional five days. Regarding the 14-day hybrid regimen, the patients received PPI and
amoxicillin 1 g for 14 days, with the addition of 500 mg clarithromycin and 500 mg metronidazole for
the final seven days, all b.i.d.. In case of failure, second line rescue treatment involves the concomitant
administration of levofloxacin 500 mg once a day (q.d.) plus amoxicillin 1 g b.i.d. and PPI b.i.d. for 10
or 14 days. AMO; amoxicillin 1 g, CLA; clarithromycin 500 mg, METRO; metronidazole 500 mg, PPI;
proton-pump inhibitor, LEVO; levofloxacin 500 mg.
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Initially, the active substances in the regimens were collected, including the choices of PPIs.
Amoxicillin 1 g, clarithromycin 500 mg, metronidazole 500 mg and levofloxacin 500 mg constitute the
mainstay antibiotics composing the various eradication regimens; levofloxacin has been considered as
a component of the second-line salvage eradication regimen. The second pillar of Hp-I eradication
treatment, complementary to antibiotics, is based on the anti-secretory and anti-inflammatory action of
PPIs such as omeprazole 20 mg, esomeprazole 20 mg and 40 mg, rabeprazole 30 mg, pantoprazole
40 mg and lansoprazole 30 mg, which were included in our cost-calculating combinations. In our
country, a chewable form of lansoprazole 30 mg is available and was also included.
In the next two steps, two separate study subgroups worked simultaneously but independently
to detect the market prices of the aforementioned drug packages (“boite”) both for prototypes and the
most affordable generics by searching in two different sources. Two official online medical databases,
including all medicines approved by the Greek National Organization for Medicines, were conscripted
and the results were compared and verified. The first database was the official government website of
the Greek National Organization for Medicines and the second was a commercial medical platform
routinely used by healthcare professionals in Greece [19,20]. All performed calculations referred to the
current drug retail price configuration.
Finally, each drug’s cost was introduced in a summary equation per eradication treatment
regimen including all used medications: Regimen’s cost = aDrug1 + bDrug2 + . . . + zDrugν; with
Drug1, . . . , Drugν; the price of one “boite” of every used drug and a,b, . . . , z; the quantity of the
medication’s packages.
Every regimen’s cost was calculated by introducing prototype or generic prices in the equation
separately. All PPI alternatives per regimen were estimated to evaluate immiscible costs, comparing
for both prototypes and generics.
Finally, additional costs of esophagoduodenoscopy, including biopsies, C13 Urea Breath Test
(Helicobacter INFAI®Test) and serum anti-Hp antibody detection were calculated separately, as they
were constant regardless of the treatment choice.
The study protocol was not sent for approval by the ethics committees of the involved hospitals
as no patients were involved.
3. Results
One hundred and seventeen different values regarding Hp eradication treatment costs ensued
and Table 1 summarizes these results. As expected, the market price of PPIs constituted the unique
independent variable forming the total regimen cost in every therapeutic strategy; eradication
treatment regimens including pantoprazole 40 mg appeared to have the lowest prices both in the
prototype and generic groups. Moreover, regimens based on generics were more affordable than the
respective prototypes.
Second-generation PPI use (esomeprazole, rabeprazole) burdened the regimens’ costs when
compared to pantoprazole prescription. More specifically, an additional cost of 4.65 €, 5.79 € or 6.47 €
per patient was added to the prototype eradication regimen using esomeprazole 20 mg, esomeprazole
40 mg or rabeprazole 30 mg, respectively, instead of pantoprazole 40 mg, whereas the analogous
differences when using generics were 1.94 €, 2.79 € and 3.81 €, respectively.
Furthermore, our analysis showed that omeprazole 20 mg generics were the most expensive
among all PPI generics.
Additionally, the prescription of prototype regimens containing chewable lansoprazole 30 mg
proved to be the most expensive pharmaceutical choice, adding a cost of 15.53 € to 23.38 € when
compared to the most affordable alternative. Differences between the lowest and the highest cost per
regimen are illustrated in Table 2.
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Table 1. Total pharmaceutical costs per Hp non-bismuth containing eradication regimen using prototype or generic drug choices and different PPIs.
Eradication Treatment Regimens
Pharmaceutical Cost per Regimen in Euros (€)
Prototype-Based Regimens * Generic-Based Regimens *
O E(20 mg)
E
(40 mg) P R L CL O
E
(20 mg)
E
(40 mg) P ** R L CL
First Line Regimens
10-day standard triple 37.77 32.74 33.86 28.09 34.56 38.28 38.59 26.35 23.09 23.94 21.15 24.98 26.30 -
14-day standard triple 54.77 49.74 50.86 45.09 51.56 55.28 55.59 37.41 34.15 35.00 32.21 36.04 37.36 -
10-day sequential 38.57 33.54 34.66 28.89 35.36 39.08 39.39 27.15 23.89 24.74 21.95 25.78 27.10 -
14-day sequential 54.00 46.96 48.52 40.45 49.50 54.71 55.15 38.01 33.45 34.64 30.73 36.09 37.94
10-day concomitant non-bismuth quadruple 42.55 37.52 38.64 32.87 39.34 43.06 43.37 31.13 27.87 28.72 25.93 29.76 31.08 -
14-day concomitant non-bismuth quadruple 59.55 54.52 55.64 49.87 56.34 60.06 60.37 42.19 38.93 39.78 36.99 40.82 42.14 -
14-day hybrid 42.55 37.52 38.64 32.87 39.34 43.06 43.37 31.13 27.87 28.72 25.93 29.76 31.08 -
Second Line Salvage Regimens
10-day levofloxacin-containing triple regimen 31.03 26.00 27.12 21.35 27.82 31.54 31.85 21.16 17.90 18.75 15.96 19.79 21.11 -
14-day levofloxacin-containing triple regimen 36.16 31.13 32.15 26.48 32.95 36.67 36.98 25.21 21.95 22.80 20.01 23.84 25.16 -
* Prototype and generic drug subgroups include prototype and generic antibiotics respectively; ** Regimens with generics and pantoprazole are the most affordable treatment choice for Hp
eradication. O: Omeprazole, E: Esomeprazole, P: Pantoprazole, R: Rabeprazole, L: Lansoprazole, CL: chewable Lansoprazole.
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Table 2. Mean cost per eradication treatment regimen and price difference between the most expensive
choice * and the most affordable one **.
Eradication Treatment Regimens Mean Cost in Euros (€) Price Difference in Euros (€)
First Line Regimens
10-day standard triple 29.98 17.44
14-day standard triple 44.24 23.38
10-day sequential 30.78 17.44
14-day sequential 43.09 24.42
10-day concomitant non-bismuth quadruple 34.76 17.44
14-day concomitant non-bismuth quadruple 49.02 23.38
14-day hybrid 34.76 17.44
Second Line Salvage Regimens
10-day levofloxacin-containing triple regimen 23.72 15.89
14-day levofloxacin-containing triple regimen 28.58 16.96
* The most expensive choice includes prototypes containing chewable lansoprazole; ** the most affordable choice
includes generics containing pantoprazole.
Paradoxically, the 10-day concomitant as well as the 14-day hybrid regimens, although differing in
duration and medication doses, costed equally. Finally, the 14-day triple regimen was more expensive
than the aforementioned regimens, which are suggested as the most appropriate in our region.
Table 3 describes the non-pharmaceutical costs of Hp-I management.
Table 3. Non-pharmacological costs of Hp-I diagnostic evaluations *.
Intervention Cost in Euros (€)
Esophagogastroduodenoscopy 77
Serum anti-Hp antibodies 13.60
C13 Urea Breath Test (Helicobacter Test INFAI®) 30.36
Gastric histology using Giemsa stain 27.76
* Based on the resource costs supplied by the Greek National Organization for Health Care Benefits Provision, Hp-I;
Helicobacter pylori infection.
4. Discussion
To our knowledge, this is the first study that has summarized and compared the total pharmaceutical
costs of approved and routinely prescribed Hp eradication regimens and PPI variants based on the current
market retail prices. Recently, De Francesco et al. [21] presented a relative comparison between regimens
used in Italy but did not estimate the different costs between prototypes and generics or PPI alternatives.
In addition, in our study, a direct comparison referring to medication prices was performed between
prototype- and generic-based eradication regimens. As expected, the generic-based alternatives were
more affordable than prototypes per regimen, and those using pantoprazole 40 mg as a PPI had the
lowest price. Additionally, 10-day concomitant and 14-day hybrid eradication regimens, both with
acceptable eradication rates in Greece, necessitate equal expenditures [17,22,23].
High antibiotic resistance has provoked a gradual escalation of eradication treatment regimens,
following an “add-on” strategy, especially in regions such as in Greece where bismuth containing
medications are not commercially available [18,24,25]. Hp resistance to clarithromycin (>20%) has been
recognized as the most determinant hindrance of eradication treatment success [26] and in that setting,
quadruple regimens are indicated [10,27]. However, in Greece, despite clear statements in current
guidelines, some practitioners (especially non-gastroenterologists) insist on prescribing triple regimens.
The 10-day triple regimen, despite being more affordable, yields unacceptable eradication rates in
Greece [28,29] and the 14-day triple regimen, which only slightly increases effectiveness, consumes
more funds compared to the indicated concomitant and hybrid schemes. Recent studies suggest that
the 10-day concomitant and the 14-day hybrid are the most appropriate and effective regimens against
Hp-I in the Greek environment when compared with the 10-day sequential treatment [17,22,23]. More
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specifically, eradication rates of 90.6–93.4% and 90.2% were yielded using the 10-day concomitant and
the 14-day hybrid regimens, respectively [17,22,23]. Both schemes were found economically equal in
our study, thus providing clinicians the flexibility to choose the most suitable for each patient, targeting
best compliance. This paradox can be explained by considering the national policy on drug disposal.
Pharmacies provide drugs in packages instead of the precise necessary quantity. Regarding the 10-day
concomitant regimen, 20 tablets of amoxicillin 1 g are needed, whereas for the 14-day sequential, 28 are
needed. Given that one package of amoxicillin 1 g contains 18 tablets, patients receive two packages
(36 tablets) irrespective of the prescribed regimen. It should be noted that the 10-day concomitant
regimen seems to achieve slightly higher eradication rates than the hybrid one and therefore further
evaluation and cost–benefit analyses are necessary, including multiple variables, such as adverse effect
expenditures, hospitalizations and Hp-I complication costs to draw conclusions regarding the most
appropriate scheme.
A financial comparison between prototype- and generic-based regimens has been conducted
in our study, although the results were what we expected. Despite the fact that generic drugs are
generally more affordable, since recently, medical practitioners in Greece had been routinely prescribing
prototypes [4]. An absence of clinical studies surveying the theoretical equality between prototypes
and generics resulted in a subconscious doubt regarding effectiveness and/or safety of generics not only
among doctors, but also among patients (at least the most “suspicious” of them) [5]. Furthermore, in
Greece, there is lack of a disincentive for prescribing prototypes instead of generics, as the extra cost for
the patient is actually negligible. The economic difference between the most affordable prototype-based
10-day concomitant eradication regimen and the respective generic one was 6.94 €. In concordance
with government policy, patients are charged 25% of the prescription value, i.e., an extra cost of only
1.74 €. It is obvious that actions are needed, both in the form of disincentives for prescribing prototypes
as well as studies on the efficacy and safety of generics.
A further novelty of our study was the direct economic comparison between PPI alternatives,
although controversial data are reported regarding the most appropriate PPI component of Hp
eradication schemes [29,30]. New generation PPIs, especially esomeprazole, have been proposed
to be more effective than first generation options, although distinct pathophysiological mechanisms
(such as CYP2C19 polymorphisms) are not yet clear [29,30]. Georgopoulos et al. and Apostolopoulos
et al., although not performing a head-to-head comparison between different PPIs, presented slightly
different eradication rates between esomeprazole 40 mg and pantoprazole 40 mg based schemes in
the same population, implying esomeprazole superiority [17,22]. More specifically, the per protocol
eradication rates of esomeprazole 40 mg based 10-day concomitant and 10-day sequential regimens
were 93.4% and 82.8%, whereas the corresponding percentages using pantoprazole 40 mg were
90.6% and 78.1% respectively [17,22]. With regard to pharmaceutical costs, our study focused on the
comparison between eradication regimens differing in PPIs, with pantoprazole 40 mg based regimens
being the most affordable, combined with either prototypes or generics. Consequently, PPIs determined
the overall costs of eradication regimens both in prototype and generic subgroups. When applying
a classification from the lowest to the highest total price for any regimen, generic-based regimens
using pantoprazole 40 mg were the most affordable, followed by esomeprazole 20 mg, esomeprazole
40 mg, rabeprazole 30 mg, lansoprazole 30 mg and omeprazole 20 mg generic regimens. Regarding
prototypes regimens, pantoprazole 40 mg, esomeprazole 20 mg, esomeprazole 40 mg, rabeprazole
30 mg, omeprazole 20 mg, lansoprazole 30 mg and finally chewable lansoprazole 30 mg were the
most expensive alternatives. The plethora of PPI choices requires clarification of their individual
role in Hp eradication concerning and comparing not only their clinical effectiveness, but also their
cost effectiveness.
The main limitation of our study was the isolated economical evaluation of Hp-I eradication
treatment without performing multivariate cost–benefit or cost-utility analyses to compare the available
eradication regimens. Nevertheless, the current study provided the initial stimulus suggesting further
prospective national studies to provide a national consensus based on eradication rates, antibiotic
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resistance and cost effectiveness, especially after the dynamic alterations of the Greek population
during the recent migratory flows [31–34]. As bismuth-based regimens are not commercially available
in our country, we could not collect financial data and include them in our study. Additionally, a wide
spectrum of Hp-I management costs needs to be considered in further studies, including diagnostic
tests, potential eradication failures and second line treatment costs, hospitalizations, complications
and any expenditure resulting from disorders related to Hp-I and its eradication treatment. Finally,
a snapshot of drug retail prices has been used and fluctuations could not be predicted in this study.
Therefore, a constant evaluation of treatment costs is necessary to secure a national management of
healthcare funds.
5. Conclusions
In conclusion, this is the first study, at least in our country, evaluating and comparing Hp eradication
treatment regimens from an economical aspect. Generic-based regimens (and more specifically those
using pantoprazole as a PPI) achieve the lowest prices and national studies comparing the efficacy
of generics and prototypes seem to be necessary. Our data should be taken into account by public
health policymakers and physicians both in Greece and the European Union, aiming for a better and
less expensive therapeutic approach. In Greece, during the financial crisis, healthcare policymakers
have applied a restriction policy of healthcare expenditures to the detriment of long-term public health.
Nowadays, cost–utility analyses appear more than necessary to promote a combined patient-centered
and cost-restricting healthcare policy not only for Hp-I eradication, but also for every disease.
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